Clinical Trials Logo

Clinical Trial Summary

This study will compare the effectiveness of face-to-face training versus Web-based training seminars in disseminating HIV prevention interventions to nongovernmental organizations in Eastern Europe and Central Asia.


Clinical Trial Description

An estimated total of 60 million people have been infected with HIV since the first cases were reported in the early 1980s. Although the HIV/AIDS pandemic is a global crisis, certain regions have been affected more than others. The Eastern European and Central Asian region, in particular, has one of the fastest growing rates of HIV infections in the world. Most new HIV infections in this region have been occurring among injection drug users, commercial sex workers, and men who have sex with men, but the virus continues to increasingly affect the general population, too. HIV prevention interventions that are able to be disseminated to a large population are necessary. The Popular Opinion Leader (POL) intervention is an HIV prevention program that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers. Administering the POL intervention to nongovernmental organizations (NGOs) may be an effective means of assuring that the intervention is extended throughout the region. However, the best means of disseminating the POL program and assuring its full adoption by NGOs is unknown. This study will compare the effectiveness of face-to-face training versus Web-based training seminars in disseminating the POL intervention to NGOs in Eastern Europe and Central Asia.

Participation in this study will last 24 months. Potential NGOs will first undergo baseline assessments that will include an in-depth 90-minute phone interview with the NGO director and completion of attitude scales about the POL HIV intervention. NGOs will then be assigned randomly to one of three study groups:

- Participating NGOs in Group 1 will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.

- Participating NGOs in Group 2 will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum. Staff will also be offered individualized telephone follow-up consultations concerning POL implementation.

- Participating NGOs in Group 3 will receive no intervention.

All participating NGOs will undergo follow-up assessments 12 and 24 months after completing the intervention training. Assessments will include a 90-minute phone interview with the NGO director and a 10-minute phone interview with NGO staff members to assess attitudes concerning the intervention, their adoption of the core elements of the intervention model, and the extent of usage of training materials. A number of NGOs that report full adoption of the POL intervention will be selected randomly to undergo a 2-day validation site visit by an assessment team member. Site visits will be used to conduct interviews with NGO staff and the opinion leaders, validate reports of intervention adoption, observe POL sessions, and review materials used in training sessions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00698529
Study type Interventional
Source Medical College of Wisconsin
Contact
Status Completed
Phase Phase 2
Start date November 2008
Completion date July 1, 2019

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2